JP2009522281A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522281A5
JP2009522281A5 JP2008548731A JP2008548731A JP2009522281A5 JP 2009522281 A5 JP2009522281 A5 JP 2009522281A5 JP 2008548731 A JP2008548731 A JP 2008548731A JP 2008548731 A JP2008548731 A JP 2008548731A JP 2009522281 A5 JP2009522281 A5 JP 2009522281A5
Authority
JP
Japan
Prior art keywords
compound
group
formula
groups
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008548731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522281A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/049450 external-priority patent/WO2007123579A2/en
Publication of JP2009522281A publication Critical patent/JP2009522281A/ja
Publication of JP2009522281A5 publication Critical patent/JP2009522281A5/ja
Pending legal-status Critical Current

Links

JP2008548731A 2005-12-28 2006-12-28 翻訳機能障害に基づく治療法 Pending JP2009522281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75446105P 2005-12-28 2005-12-28
US79404806P 2006-04-22 2006-04-22
US84858306P 2006-09-29 2006-09-29
US85440406P 2006-10-25 2006-10-25
PCT/US2006/049450 WO2007123579A2 (en) 2005-12-28 2006-12-28 Translational dysfunction based therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015182943A Division JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Publications (2)

Publication Number Publication Date
JP2009522281A JP2009522281A (ja) 2009-06-11
JP2009522281A5 true JP2009522281A5 (https=) 2013-04-11

Family

ID=38625451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008548731A Pending JP2009522281A (ja) 2005-12-28 2006-12-28 翻訳機能障害に基づく治療法
JP2015182943A Pending JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015182943A Pending JP2016040263A (ja) 2005-12-28 2015-09-16 翻訳機能障害に基づく治療法

Country Status (6)

Country Link
EP (1) EP1971690B1 (https=)
JP (2) JP2009522281A (https=)
AU (1) AU2006342447B2 (https=)
CA (1) CA2633715C (https=)
NZ (1) NZ569883A (https=)
WO (1) WO2007123579A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602349B2 (ja) * 2007-11-20 2014-10-08 旭化成ファーマ株式会社 ミゾリビン及び/又はリバビリンの測定方法
WO2009118712A2 (en) * 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
US8599383B2 (en) 2009-05-06 2013-12-03 The Regents Of The University Of California Optical cytometry
CA2843445C (en) 2011-08-02 2019-09-24 The Regents Of The University Of California Rapid, massively parallel single-cell drug response measurements via live cell interferometry
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
JP6367318B2 (ja) 2013-05-24 2018-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 質量応答における変化による望ましいtリンパ球の同定
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FI71768C (fi) 1984-02-17 1987-02-09 Orion Yhtymae Oy Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning.
GB8432118D0 (en) 1984-12-19 1985-01-30 Malcolm A D B Sandwich hybridisation technique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
EP0980280B1 (en) 1997-10-01 2005-02-09 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6230802B1 (en) 1998-07-24 2001-05-15 Schlumberger Technology Corporation Method and apparatus for gravel packing a well
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2003073989A2 (en) * 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
CA2566874C (en) * 2003-05-15 2014-07-08 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER

Similar Documents

Publication Publication Date Title
CN111107853B (zh) 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
ES2924806T3 (es) Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo
ES2344566T3 (es) Compuestos oligomericos para la modulacion de bcl-2.
JP2010538677A5 (https=)
JP2019059789A (ja) 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
KR20060109443A (ko) 향상된 면역자극 효능을 가진 c-부류 올리고뉴클레오티드유사체
JP2012504129A5 (https=)
KR20190040033A (ko) 가역적으로 변형된 올리고뉴클레오티드를 포함하는 조성물 및 그의 용도
KR20150028352A (ko) 키랄 핵산 어쥬번트
KR20090057468A (ko) 톨-유사 수용체(tlr) 리간드 및 항바이러스제의 조성물
JP2013138681A5 (https=)
JP2021522862A (ja) 7’−5’−アルファ−アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
JP2006515277A (ja) C型肝炎ウィルス感染の処置および予防に関する方法および製品
JPWO2021030778A5 (https=)
JP2009524696A5 (https=)
JP2008506683A (ja) 先天免疫応答を誘導するための方法および組成物
JP2006518197A5 (https=)
RU2005133711A (ru) Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины
EP3043823A1 (en) Antisense oligonucleotides with improved pharmacokinetic properties
MXPA06009794A (es) Composicion farmaceutica.
KR20150131365A (ko) 브리지드 바이사이클릭 뉴클레오시드
EP2857513A1 (en) Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
JP2009522281A5 (https=)
JPWO2022028462A5 (https=)
JP2024545052A (ja) 修飾骨格化学を有するスプライススイッチャーアンチセンスオリゴヌクレオチド